Alaunos Therapeutics M&A Deal with Velaris Therapeutics, Inc.
Alaunos Therapeutics completed the acquisition of Velaris Therapeutics through a two-step merger process, making Velaris a wholly owned subsidiary. As consideration, Alaunos issued 105,286 shares of Series B Preferred Stock and 33,054 shares of Series C Preferred Stock to Velaris stockholders, which are convertible into common stock subject to shareholder approval. Following the deal, Alaunos plans to change its name to Velaris Therapeutics, Inc. and effect a reverse stock split.
- Counterparty
- Velaris Therapeutics, Inc.